Biogen (BIIB.US) stock has been halted after the FDA has approved its controversial Alzheimer drug Aducanumab using an accelerated approval pathway. It is the first Alzheimer's treatment approved in 18 years, according to CNBC. Biogen still needs to conduct a postapproval clinical trial and FDA pointed out that the approval may be withdrawn upon unfavorable results.
Biogen (BIIB.US) stock was halted for trading at $286.10 and awaits reopening. Source: xStation5
AI Needs Data. Is That Why Western Digital Is Surging?
NVIDIA looks for a new path to China. Vera CPUs could open an alternative growth channel
US Open: Wall Street in Euphoria After Announcement of U.S.–Iran Agreement
SpaceX shares gain 6% in pre-market 📈